We are delighted to welcome Longboat Energy CEO Helge Hammer and BD Director Nick Ingrassia #LBE to Tuesday’s live webinar. They join Atlantic Lithium CEO Vincent Mascolo #ALL #IRR, Cora Gold CEO Bert Monro #CORA and Valirx CEO Suzanne Dilly #VAL. Please register here

Less Ads, More Data, More Tools Register for FREE

UPDATE 1-AstraZeneca aims at 2 bln doses with new COVID vaccine deals

Thu, 4th Jun 2020 17:00

(Adds details from Gavi, CEPI statements, context)

June 4 (Reuters) - Britain's AstraZeneca will be
able to deliver 2 billion doses of its potential coronavirus
vaccine this year and next, double the previous numbers, thanks
to deals with the Serum Institute of India and two Bill
Gates-backed global health organisations.

The company, which has already agreed to supply 400 million
doses to the United States and British governments, said on
Thursday it had agreed terms with the Indian company, the
world's largest manufacturer of vaccines by volume, to supply
one billion doses for low and middle-income countries.

AstraZeneca's partnership with Oxford University has
garnered international attention as one of the leading
coronavirus vaccine candidates, sealing more than $1 billion in
U.S. government funding last month as it ramps up testing of the
vaccine and manufacturing capacity.

It said it had also signed an agreement worth $750 million
with the Coalition for Epidemic Preparedness Innovations (CEPI)
and GAVI vaccines alliance, both founded by Microsoft-founder
Gates and his wife, to produce 300 million doses of the vaccine.

GAVI said on Thursday it had raised $2 billion from
international donors for an Advanced Market Commitment to buy
future COVID-19 vaccines for poor countries, including a $100
million commitment from the Bill & Melinda Gates Foundation
(Reporting by Pushkala Aripaka in Bengaluru and Kate Kelland in
London; Editing by Saumyadeb Chakrabarty and Patrick Graham)

Related Shares

More News

Two Hutchmed drugs included in China's 2022 reimbursement list

(Sharecast News) - Hutchmed China announced on Friday that, following negotiations with the China National Healthcare Security Administration (NHSA), from 1 January the updated National Reimbursement Drug List (NRDL) will continue to include 'Elunate', or fruquintinib, and would now include 'Sulanda', or surufatinib.

3 Dec 21 13:23

Omicron cases outside South Africa no deadlier, Australian official says

(Sharecast News) - On current evidence, the Omicron variant of Covid-19 did not yet appear to be any deadlier than previous ones, Australian health officials said.

2 Dec 21 08:40

All confirmed Omicron cases in EU thus far are asymptomatic or have shown mild symptoms

(Sharecast News) - All confirmed cases of the Omicron variant of concern detected thus far in the European Union had thus far had been either asymptomatic or shown "mild" symptoms, the bloc's pandemic watchdog said.

30 Nov 21 21:49

AstraZeneca cancer drug Lynparza is granted priority review in US

AstraZeneca cancer drug Lynparza is granted priority review in US

30 Nov 21 09:52

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.